Diamyd Medical Partners with JDRF to Revolutionize Type 1 Diabetes Treatment

Date:

Diamyd Medical, a company specializing in precision medicine therapies for Type 1 Diabetes, has partnered with the JDRF (Juvenile Diabetes Research Foundation) to revolutionize the treatment of this condition. The partnership aims to develop new strategies for immunomodulatory approaches in Type 1 Diabetes and is focused on Diamyd’s antigen-specific immunotherapy, Diamyd®.

In an upcoming webcast presentation on October 20th, Diamyd Medical’s CEO, Ulf Hannelius, along with Josh Vieth, Director of Research at JDRF, and Mark Atkinson, Director for the University of Florida Diabetes Institute, will discuss the progress and potential of Diamyd® in a Phase 3 trial known as DIAGNODE-3. This antigen-specific immunotherapy is designed to preserve endogenous insulin production in patients with Type 1 Diabetes.

The presentation, hosted by News Agency Direkt and Direkt Studios, will provide an overview of the industry partnership between Diamyd Medical and JDRF, which was first announced in April of this year. The focus will be on the ongoing DIAGNODE-3 trial and the promising results that have been seen so far.

Diamyd Medical’s Diamyd® has shown significant results in previous studies, including a large-scale meta-analysis and the Company’s European Phase IIb trial DIAGNODE-2. In this trial, the immunotherapy was administered directly into a lymph node in children and young adults with recently diagnosed Type 1 Diabetes.

To further support its precision medicine therapies, Diamyd Medical is establishing a biomanufacturing facility in Umeå, Sweden, for the production of recombinant GAD65, the active ingredient in Diamyd®. The company is also involved in the development of Remygen®, a GABA-based investigational drug aimed at regenerating endogenous insulin production.

With its B-share listed on Nasdaq First North Growth Market under the ticker DMYD B, Diamyd Medical continues to pursue innovative solutions for Type 1 Diabetes treatment. The company is also a major shareholder in NextCell Pharma AB, a stem cell company, and MainlyAI AB, an artificial intelligence company.

See also  Unlocking the Mystery of Dark Energy: AI Reveals Cosmic Secrets

For further information about Diamyd Medical and its groundbreaking research, interested parties can reach out to their President and CEO, Ulf Hannelius, who can be contacted via phone at +46 736 35 42 41 or by email at ulf.hannelius@diamyd.com.

In conclusion, the partnership between Diamyd Medical and JDRF represents a significant step towards revolutionizing the treatment of Type 1 Diabetes. Through their collaborative efforts, they aim to develop innovative immunomodulatory approaches and advance the antigen-specific immunotherapy, Diamyd®, in order to improve the lives of those affected by this chronic condition.

Frequently Asked Questions (FAQs) Related to the Above News

What is Diamyd Medical?

Diamyd Medical is a company specializing in precision medicine therapies for Type 1 Diabetes. Their focus is on developing immunomodulatory approaches, specifically their antigen-specific immunotherapy called Diamyd®.

What is the partnership between Diamyd Medical and JDRF?

Diamyd Medical has partnered with JDRF (Juvenile Diabetes Research Foundation) to revolutionize the treatment of Type 1 Diabetes. The partnership aims to develop new strategies for immunomodulatory approaches and focuses on advancing Diamyd's antigen-specific immunotherapy.

What is the DIAGNODE-3 trial?

The DIAGNODE-3 trial is a Phase 3 trial involving Diamyd®. It is designed to evaluate the effectiveness of the antigen-specific immunotherapy in preserving endogenous insulin production in patients with Type 1 Diabetes.

When and where will the webcast presentation take place?

The webcast presentation will take place on October 20th and will be hosted by News Agency Direkt and Direkt Studios.

What will be discussed in the webcast presentation?

The webcast presentation will discuss the progress and potential of Diamyd® in the DIAGNODE-3 trial. CEO Ulf Hannelius, along with Josh Vieth from JDRF and Mark Atkinson from the University of Florida Diabetes Institute, will provide an overview of the industry partnership and the promising results seen so far.

What are the previous results of Diamyd®?

Diamyd® has shown significant results in previous studies, including a large-scale meta-analysis and the European Phase IIb trial DIAGNODE-2. These studies involved administering the immunotherapy directly into a lymph node in children and young adults with recently diagnosed Type 1 Diabetes.

What is Diamyd Medical's involvement in biomanufacturing?

Diamyd Medical is establishing a biomanufacturing facility in Umeå, Sweden, for the production of recombinant GAD65, which is the active ingredient in Diamyd®. This facility will support their precision medicine therapies.

What other projects is Diamyd Medical involved in?

Diamyd Medical is a major shareholder in NextCell Pharma AB, a stem cell company, and MainlyAI AB, an artificial intelligence company. They are also involved in the development of Remygen®, a GABA-based investigational drug aimed at regenerating endogenous insulin production.

How can interested parties get more information about Diamyd Medical?

Interested parties can reach out to Diamyd Medical's President and CEO, Ulf Hannelius, through phone at +46 736 35 42 41 or by email at ulf.hannelius@diamyd.com. They can provide further information about the company and its groundbreaking research.

What is the goal of the partnership between Diamyd Medical and JDRF?

The partnership aims to revolutionize the treatment of Type 1 Diabetes by developing innovative immunomodulatory approaches and advancing the antigen-specific immunotherapy, Diamyd®, to improve the lives of individuals affected by this chronic condition.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

Tesla Shareholders Approve $56B Musk Pay Package, Texas Move

Tesla shareholders approve Elon Musk's $56B pay package and Texas move. Will this boost confidence in Musk's leadership at Tesla?

Asian Shares Rise as Investors Eye Bank of Japan Monetary Policy Decision

Asian shares rise as investors await Bank of Japan's monetary policy decision. Market optimism grows amid potential interest rate cuts.

Dispute Over Gene-Edited Crop Patents Engulfs Europe

The heated debate over gene-edited crop patents in Europe is sparking controversy over intellectual property rights in agriculture.

Elon Musk’s Warning on Apple’s Data Sharing Sparks Controversy

Elon Musk sparks controversy with Apple's data sharing warning, while Tamil producer Bava thanks Musk for meme featuring his film poster.